Return to homepagePandemic Pact

Testing of SARS-CoV-2 Infectivity and Antiviral Drug Effects in Engineered Heart Tissue, Microglial Cell Models, and COVID-19 Patient Registries

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    American Heart Association

  • Research Location

    United States of America

  • Lead Research Institution

    Cleveland Clinic

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

This team will use a multidisciplinary approach to 1) study the interaction of SARS-CoV-2 spike protein in cardiac and brain cells, 2) screen possible candidate drugs targeting mechanisms of viral infection in these cells, and 3) assess these drugs using AHA's COVID-19 registry. Expected outcomes include identification of drugs that can be repurposed and advanced toward clinical trials for treatment of COVID-19.